We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+21.61%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$3.64B
AUM Growth
-$358M
Cap. Flow
-$561M
Cap. Flow %
-15.41%
Top 10 Hldgs %
62.29%
Holding
72
New
2
Increased
4
Reduced
13
Closed
10

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$77M
2
TYRA icon
Tyra Biosciences
TYRA
+$31.5M
3
ALLK
Allakos
ALLK
+$12.4M
4
IMUX icon
Immunic
IMUX
+$11.6M
5
UNCY icon
Unicycive Therapeutics
UNCY
+$1.81M

Top Sells

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$158M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$69.8M
3
MRUS
Merus
MRUS
+$64.1M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$54.1M
5
KURA icon
Kura Oncology
KURA
+$50.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANTX icon
51
AN2 Therapeutics
ANTX
$193M
$4.03M 0.11%
1,239,470
-324,493
-21% -$3.53M
KRON
52
DELISTED
Kronos Bio
KRON
$3.78M 0.1%
2,905,043
– –
PVLA
53
Palvella Therapeutics
PVLA
$2.02B
$3.78M 0.1%
257,623
– –
VIRX
54
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.69M 0.1%
3,614,662
– –
IVA
55
Inventiva
IVA
$1.04B
$2.48M 0.07%
686,040
– –
FBRX icon
56
Forte Biosciences
FBRX
$1.57B
$2.09M 0.06%
119,284
– –
MOLN
57
Molecular Partners
MOLN
$1.72M 0.05%
443,221
– –
MTEM
58
DELISTED
Molecular Templates, Inc.
MTEM
$1.17M 0.03%
522,238
-9,800
-2% -$33K
NCEL
59
NewcelX Ltd
NCEL
$18.7M
$1.04M 0.03%
14,368
– –
ASLN
60
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$646K 0.02%
131,250
– –
CRVS icon
61
Corvus Pharmaceuticals
CRVS
$1.1B
$643K 0.02%
361,406
-1,009,541
-74% -$2.11M
RZLT icon
62
Rezolute
RZLT
$445M
$487K 0.01%
190,815
– –
AXSM icon
63
Axsome Therapeutics
AXSM
$11.2B
– –
-1,981,100
Closed -$158M
CNTA
64
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-8,774,570
Closed -$69.8M
IMVT icon
65
Immunovant
IMVT
$7.85B
– –
-300,000
Closed -$12.6M
ITOS
66
DELISTED
iTeos Therapeutics
ITOS
– –
-1,259,476
Closed -$13.8M
RLAY icon
67
Relay Therapeutics
RLAY
$4.04B
– –
-3,970,045
Closed -$43.7M
SLN
68
Silence Therapeutics
SLN
$525M
– –
-1,508,416
Closed -$26.2M
STRO icon
69
Sutro Biopharma
STRO
$403M
– –
-334,795
Closed -$14.4M
SYRE icon
70
Spyre Therapeutics
SYRE
$8.49B
– –
-687,080
Closed -$14.8M
XENE icon
71
Xenon Pharmaceuticals
XENE
$6.08B
– –
-890,072
Closed -$41M
RAIN
72
DELISTED
Rain Oncology Inc. Common Stock
RAIN
– –
-3,526,729
Closed -$4.23M
1 2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2024 Portfolio in Review

As of Q1 2024, BVF Inc held 72 positions worth $3.64B, down 9% from $4B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

BVF Inc withdrew a net $561M in Q1 2024, closing 10 positions and reducing 13 holdings. Its most notable exit was Axsome Therapeutics, an estimated $158M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, BVF Inc opened a new position in CG Oncology worth $82.7M.

  • BVF Inc's largest Q1 2024 buy was CG Oncology: 1,884,191 shares worth $82.7M.
  • BVF Inc added most to Tyra Biosciences in Q1 2024, an estimated $31.5M increase.
  • BVF Inc's biggest Q1 2024 reduction was Merus, cutting an estimated $64.1M.
  • BVF Inc fully exited Axsome Therapeutics in Q1 2024, selling an estimated $158M.
  • BVF Inc's ten largest holdings make up 62% of its $3.64B portfolio in Q1 2024.
  • BVF Inc opened 2 new positions and closed 10 in Q1 2024.
  • BVF Inc's portfolio value fell 9% quarter-over-quarter to $3.64B.

Based on BVF Inc's 13F filing for Q1 2024, filed 15 May 2024.